Publication number: 20210401916
Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
Type:
Application
Filed:
September 20, 2021
Publication date:
December 30, 2021
Applicants:
Industry-Academic Cooperation Foundation, Yonsei University, Cosmax NBT, Inc., Cosmax NS, Inc.
Inventors:
Jae Kwan HWANG, Jun Gon YUN, Mi Bo KIM, Chang Hee KIM, Joon Hyung LEE, Do Wan KWON, Su Young CHOI, Jin Hak KIM, Ji Hwan JANG, Jeong Ho GEUM, Min Son KWEON
Patent number: 11160840
Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
Type:
Grant
Filed:
November 30, 2017
Date of Patent:
November 2, 2021
Assignees:
Industry-Academic Cooperation Foundation, Yonsei University, Cosmax NBT, Inc., Cosmax NS, Inc.
Inventors:
Jae Kwan Hwang, Jun Gon Yun, Mi Bo Kim, Chang Hee Kim, Joon Hyung Lee, Do Wan Kwon, Su Young Choi, Jin Hak Kim, Ji Hwan Jang, Jeong Ho Geum, Min Son Kweon
Publication number: 20200009208
Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
Type:
Application
Filed:
November 30, 2017
Publication date:
January 9, 2020
Applicants:
Industry-Academic Cooperation Foundation, Yonsei University, Cosmax NBT, Inc., Cosmax NS, Inc.
Inventors:
Jae Kwan HWANG, Jun Gon YUN, Mi Bo KIM, Chang Hee KIM, Joon Hyung LEE, Do Wan KWON, Su Young CHOI, Jin Hak KIM, Ji Hwan JANG, Jeong Ho GEUM, Min Son KWEON